Wellington Management Group LLP Sells 340,938 Shares of Charles River Laboratories International, Inc. $CRL

Posted by Geri Gentry on Aug 31st, 2026

Wellington Management Group LLP reduced its stake in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 20.9% during the second quarter, HoldingsChannel.com reports. The firm owned 1,288,463 shares of the medical research company’s stock after selling 340,938 shares during the quarter. Wellington Management Group LLP’s holdings in Charles River Laboratories International were worth $292,211,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Los Angeles Capital Management LLC bought a new position in Charles River Laboratories International during the 4th quarter valued at approximately $42,000. Sfam LLC bought a new stake in Charles River Laboratories International in the fourth quarter worth $43,000. Elyxium Wealth LLC purchased a new stake in shares of Charles River Laboratories International in the fourth quarter worth $46,000. Geneos Wealth Management Inc. grew its stake in shares of Charles River Laboratories International by 98.0% in the second quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock worth $44,000 after acquiring an additional 145 shares during the last quarter. Finally, Allworth Financial LP raised its position in shares of Charles River Laboratories International by 61.3% in the 4th quarter. Allworth Financial LP now owns 350 shares of the medical research company’s stock worth $70,000 after purchasing an additional 133 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on CRL shares. Robert W. Baird set a $291.00 price objective on shares of Charles River Laboratories International in a research report on Thursday, August 6th. Sanford C. Bernstein set a $250.00 target price on shares of Charles River Laboratories International in a report on Wednesday, July 1st. Evercore reiterated an “outperform” rating on shares of Charles River Laboratories International in a research note on Wednesday, August 5th. CLSA downgraded shares of Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price target for the company. in a research report on Monday, July 20th. Finally, Citigroup reaffirmed a “buy” rating on shares of Charles River Laboratories International in a research report on Wednesday, July 8th. Twelve investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $255.65.

Read Our Latest Stock Report on CRL

Charles River Laboratories International Stock Performance

Shares of NYSE CRL opened at $291.80 on Monday. The firm’s 50-day moving average price is $246.06 and its 200-day moving average price is $197.39. The company has a quick ratio of 1.04, a current ratio of 1.35 and a debt-to-equity ratio of 0.92. The company has a market cap of $13.93 billion, a PE ratio of -60.16, a PEG ratio of 3.03 and a beta of 1.38. Charles River Laboratories International, Inc. has a 52-week low of $144.26 and a 52-week high of $303.30.

Charles River Laboratories International (NYSE:CRL – Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.25. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $980.53 million. During the same period in the previous year, the business posted $3.12 earnings per share. The business’s revenue for the quarter was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, analysts anticipate that Charles River Laboratories International, Inc. will post 11.33 EPS for the current year.

Key Charles River Laboratories International News

Here are the key news stories impacting Charles River Laboratories International this week:

Positive Sentiment: Long-term earnings outlook improved. Zacks Research raised its EPS forecasts for fiscal 2026 to $11.15 from $10.91, fiscal 2027 to $12.49 from $12.11, and fiscal 2028 to $13.82 from $13.01. Estimates also increased for several future quarters, signaling greater confidence in CRL’s longer-term growth prospects.
Positive Sentiment: Enterovirus vaccine collaboration could generate future demand. Medigen has partnered with Charles River in an effort to bring an enterovirus vaccine to global markets. The initiative could create additional opportunities for CRL’s contract research, testing, and development services. Medigen links up with Charles River in push to take enterovirus vaccine global
Neutral Sentiment: Recent operating results provide a mixed backdrop. CRL’s latest quarterly EPS of $3.02 exceeded the $2.77 consensus estimate, and revenue reached approximately $1 billion. However, revenue declined 2.7% year over year, while the company’s full-year 2026 EPS guidance remains $11.15-$11.45, close to the analyst consensus.
Negative Sentiment: Director sold a sizable stake. James C. Foster sold 33,561 shares for about $10.1 million at an average price of $300, reducing his direct ownership by 51.5%. The transaction was made under a pre-arranged Rule 10b5-1 plan, which makes it a less definitive bearish signal, but the size of the sale may pressure investor sentiment. SEC insider transaction filing
Negative Sentiment: Some near-term estimates were lowered. Zacks trimmed its EPS forecasts for the third and fourth quarters of 2026, the first quarter of 2027, and the fourth quarter of 2027. These modest cuts suggest near-term uncertainty despite the stronger full-year and longer-term projections.

Insiders Place Their Bets

In other Charles River Laboratories International news, EVP Victoria L. Creamer sold 4,179 shares of the business’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $259.16, for a total transaction of $1,083,029.64. Following the completion of the sale, the executive vice president directly owned 30,051 shares in the company, valued at approximately $7,788,017.16. The trade was a 12.21% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Birgit Girshick sold 6,500 shares of the business’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $279.90, for a total transaction of $1,819,350.00. Following the sale, the chief executive officer owned 36,013 shares of the company’s stock, valued at approximately $10,080,038.70. This represents a 15.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 165,990 shares of company stock worth $42,606,388 in the last 90 days. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Company Profile

(Free Report)

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.